| Bioactivity | Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA[1]. |
| CAS | 1848239-71-3 |
| Formula | C361H411N141O262Na36P36 |
| Molar Mass | 12859.67 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Anne-Marie Bleau, et al. Development of tivanisiran, a topical siRNA designed to [2]. Javier Moreno-Montañés, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. |
Tivanisiran sodium
CAS: 1848239-71-3 F: C361H411N141O262Na36P36 W: 12859.67
Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transien
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.